Journal
BRITISH JOURNAL OF CANCER
Volume 112, Issue 2, Pages 217-226Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/bjc.2014.476
Keywords
melanoma; targeted therapy; beyond BRAF
Categories
Funding
- SPORE from the National Institutes of Health [P50 CA168536-01A1]
- [R01 CA161107-01]
Ask authors/readers for more resources
In recent years, melanoma has become a poster-child for the development of oncogene-directed targeted therapies. This approach, which has been exemplified by the development of small-molecule BRAF inhibitors and the BRAF/MEK inhibitor combination for BRAF-mutant melanoma, has brought new hope to patients. Despite these successes, treatment failure seems near inevitable in the majority of cases-even in individuals treated with the BRAF/MEK inhibitor doublet. In the current review, we discuss the future of combination strategies for patients with BRAF-mutant melanoma as well as the emerging therapeutic options for patients with NRAS-mutant and BRAF/NRAS-wild-typemelanoma. We also outline some of the newest developments in the in-depth personalisation of therapy that should allow melanoma treatment to continue shaping the field precision cancer medicine.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available